Neuland Laboratories Ltd.

₹14,445

-310 (-2.1%)

NEULANDLAB Share Price

Pharmaceuticals & Biotechnology

As on April 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 18,565 Cr

P/E Ratio71.25

Dividend Yield0.01 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	14,729.8	Bearish
10-DMA	14,904.8	Bearish
20-DMA	14,141.35	Bullish
50-DMA	13,317.44	Bullish
100-DMA	14,054.18	Bullish
200-DMA	14,517.52	Bearish

Historical Performance

1 Year

14.9%

3 Years

575.3%

5 Years

489.1%

10 Years

1799.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	14,768	15,586	11,912	9,511	9,369
Total Expenditure	11,536	10,960	9,194	8,085	7,901
Other Income	205	125	97	21	161
Operating Profit	3,438	4,751	2,816	1,447	1,629
Interest	83	140	131	135	179
Depreciation	655	597	528	490	397
Profit Before Tax	3,463	4,014	2,157	822	1,053
Consolidated Net Profit	2,601	3,001	1,635	638	806
Adjusted EPS	203	234	127	50	63

Compounded Sales Growth

10 Years:25.8

5 Years:14.1

3 Years:9.2

TTM:-1.1

Compounded Profit Growth

10 Years:74.8

5 Years:74.2

3 Years:32.4

TTM:-2.8

Stock Price CAGR

10 Years:34.4

5 Years:42.8

3 Years:89

TTM:17.7

Return on Equity

10 Years:30.8

5 Years:62.8

3 Years:127.5

last year:202.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	129	129	129	129	129
Total Reserves	15,119	12,698	9,812	8,276	7,736
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,894	1,222	1,467	1,798	1,698
Other Current Liabilities	2,113	2,340	2,449	1,523	1,587
Short Term Borrowings	---	---	112	922	570
Total Liabilities	21,799	18,326	15,798	13,835	13,248
Capital Work in Progress	446	459	406	205	173
Long Term Loans & Advances	360	405	202	144	417
Currents Investments	1,077	---	---	34	65
Short Term Loans and Advances	518	620	471	460	496
Total Current Assets	11,395	9,211	7,609	5,808	5,496
Total Assets	21,799	18,326	15,798	13,835	13,248
Adjusted Book Value	1,188	999	774	654	612

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 71.25, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 90.9%, indicating sustained price appreciation.
The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹3438 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹14768 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1176494.5

No. of Shares: 81 (Approx)

Performance:17.6%

P/L: ₹176494.5

NIFTY Performance: -1.4%

1 day Top Gainers